Immucell (ICCC) Interest & Investment Income (2018 - 2026)
Immucell's (ICCC) quarterly Interest & Investment Income came in at $31659.0 in Q4 2025, down 12.61% YoY from $36226.0 in Q4 2024, and down 23.65% on a QoQ basis from $41468.0 in Q3 2025.
Immucell (ICCC) Interest & Investment Income (2018 - 2026) Analysis & Trends
Immucell (ICCC) has 5 years of Interest & Investment Income data on file, last reported at $31659.0 in Q4 2025.
- Quarterly Interest & Investment Income fell 12.61% year-over-year to $31659.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $158709.0 (up 104.25% YoY) and the FY2025 annual result came in at $158709.0, up 104.25% from the prior year.
- Interest & Investment Income retreated to $31659.0 in Q4 2025, from $41468.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $48113.0 in Q2 2025 to a low of $9527.0 in Q1 2024.
- A 3-year average of $29184.8 and a median of $33942.5 in 2024 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2024 — Interest & Investment Income plunged 76.55% — and 2025, when it surged 293.29%.
- Tracing ICCC's Interest & Investment Income over 3 years: stood at $14806.0 in 2023, then jumped by 144.67% to $36226.0 in 2024, then decreased by 12.61% to $31659.0 in 2025.
- The last three Interest & Investment Income figures came in at $31659.0 (Q4 2025), $41468.0 (Q3 2025), and $48113.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Immucell | 91.19 Mn | 82.33 Mn | 2.44 Mn | 65,343.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 65,343.00 |
| Dec 31, 2025 | 31,659.00 |
| Sep 30, 2025 | 41,468.00 |
| Jun 30, 2025 | 48,113.00 |
| Mar 31, 2025 | 37,469.00 |
| Dec 31, 2024 | 36,226.00 |
| Sep 30, 2024 | 18,685.00 |
| Jun 30, 2024 | 13,264.00 |
| Mar 31, 2024 | 9,527.00 |
| Jun 30, 2023 | 14,806.00 |
| Mar 31, 2023 | 40,631.00 |
| Dec 31, 2019 | 27,150.00 |
| Sep 30, 2019 | 41,719.00 |
| Jun 30, 2019 | 47,099.00 |
| Mar 31, 2019 | 2,315.00 |
| Dec 31, 2018 | 4,031.00 |
| Sep 30, 2018 | 3,237.00 |
| Jun 30, 2018 | 3,209.00 |
| Mar 31, 2018 | 3,824.00 |